KalVista Pharmaceuticals, Inc. Operating Income Loss

• KalVista Pharmaceuticals, Inc. showed a decrease of -33.9% in Operating Income Loss from 2024 to 2025.
• This data is from KalVista Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 10, 2025.
• XBRL data for this metric is available from 2013 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 14 years of available data (2013 to 2025), KalVista Pharmaceuticals, Inc.'s Operating Income Loss has declined by 3,504.2%.
• Historical annual values: Fiscal year 2025: -$188.00 million | Fiscal year 2024: -$140.45 million | Fiscal year 2023: -$110.87 million | Fiscal year 2022: -$96.61 million | Fiscal year 2021: -$57.92 million | Fiscal year 2020: -$40.53 million | Fiscal year 2019: -$29.82 million | Fiscal year 2018: -$18.71 million | Fiscal year 2017: -$22.34 million | Fiscal year 2016: -$15.18 million | Fiscal year 2015: -$21.04 million | Fiscal year 2015: -$8.09 million | Fiscal year 2014: -$11.68 million | Fiscal year 2013: -$5.22 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026